Free Trial

Castle Biosciences (CSTL) Stock Forecast & Price Target

Castle Biosciences logo
$29.81 +0.93 (+3.22%)
(As of 11/22/2024 ET)

Castle Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
8

Based on 8 Wall Street analysts who have issued ratings for Castle Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for CSTL.

Consensus Price Target

$37.88
27.05% Upside
According to the 8 analysts' twelve-month price targets for Castle Biosciences, the average price target is $37.88. The highest price target for CSTL is $44.00, while the lowest price target for CSTL is $25.00. The average price target represents a forecasted upside of 27.05% from the current price of $29.81.
Get the Latest News and Ratings for CSTL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Castle Biosciences and its competitors.

Sign Up

CSTL Analyst Ratings Over Time

TypeCurrent Forecast
11/25/23 to 11/24/24
1 Month Ago
10/26/23 to 10/25/24
3 Months Ago
8/27/23 to 8/26/24
1 Year Ago
11/25/22 to 11/25/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.88$34.00$32.80$32.29
Forecasted Upside27.05% Upside8.38% Upside13.69% Upside62.40% Upside
Consensus Rating
Buy
Buy
Buy
Buy

CSTL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CSTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Castle Biosciences Stock vs. The Competition

TypeCastle BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside27.05% Upside27,073.48% Upside7.66% Upside
News Sentiment Rating
Neutral News

See Recent CSTL News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/6/2024Scotiabank
5 of 5 stars
 Boost TargetSector Outperform ➝ Sector Outperform$37.00 ➝ $44.00+33.86%
11/5/2024Lake Street Capital
3 of 5 stars
 Boost TargetBuy ➝ Buy$34.00 ➝ $40.00+28.41%
11/5/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$37.00 ➝ $39.00+15.93%
11/5/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$28.00 ➝ $36.00+7.02%
10/29/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$35.00 ➝ $42.00+29.63%
10/14/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$35.00 ➝ $40.00+21.32%
9 hidden AI stocks set to thrive in Trump’s new era (Ad)

AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)

Get the Name of These AI Picks Now
8/6/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$37.00 ➝ $37.00+45.04%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+21.65%
6/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$50.00 ➝ $35.00+194.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:45 AM ET.


CSTL Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Castle Biosciences is $37.88, with a high forecast of $44.00 and a low forecast of $25.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.

According to analysts, Castle Biosciences's stock has a predicted upside of 27.05% based on their 12-month stock forecasts.

Castle Biosciences has been rated by research analysts at BTIG Research, Canaccord Genuity Group, KeyCorp, Lake Street Capital, Robert W. Baird, and Scotiabank in the past 90 days.

Analysts like Castle Biosciences more than other "medical" companies. The consensus rating for Castle Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CSTL compares to other companies.


This page (NASDAQ:CSTL) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners